Lower respiratory tract and plasma SARS-CoV-2 RNA load in critically ill adult COVID-19 patients: Relationship with biomarkers of disease severity

Olea, Beatriz; Albert, Eliseo; Torres, Ignacio; Gozalbo-Rovira, Roberto; Carbonell, Nieves; Ferreres, José; Poujois, Sandrine; Costa, Rosa; Colomina, Javier; Rodríguez, Jesús Álvarez; Blasco, María Luisa; Navarro, David

doi:10.1016/j.jinf.2021.05.036

Cited by 13 publications

(18 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 61 patients had one or more TA collected (total number, 165; median of 2 specimens/patient; range, 1–11) within the study period. As previously reported, 10 SARS‐CoV‐2 RNA load in TA ranged between 3.03 and 10.6 log 10 copies/ml (median, 6.5 log 10 copies/ml). SARS‐CoV‐2 RNA load in TA was significantly higher ( p < 0.001) in the presence of concomitant N‐antigenemia than in its absence (Figure 2B).…”

Section: Resultssupporting

confidence: 81%

“…No patient had N‐antigenemia beyond day 32 after symptoms onset. SARS‐CoV‐2 RNAemia could be detected in 37 plasma specimens from 26 patients (35.6%) and its kinetics was similar to that of N‐antigenemia 10 . There were 30 specimens yielding discordant results (N‐antigenemia positive/RNAemia negative, n = 18, and N‐antigenemia negative/RNAemia positive, n = 12); Thus, the level of agreement between the qualitative results returned by the N‐antigenemia assay and plasma RT‐PCR was moderate ( k = 0.57; p < 0.0001).…”

Section: Resultsmentioning

confidence: 79%

“…SARS‐CoV‐2 RNA amplification was carried out by the Abbott Real Ti me SARS‐CoV‐2 assay, a dual‐target RT‐PCR assay amplifying the RdRp and N‐genes, on the m2000rt platform, following the manufacturer's instructions. The LOD was found to be approximately 100 copies/ml (95% confidence interval [CI]) 10 . SARS‐CoV‐2 viral loads in plasma and TA are given in copies/ml throughout the study, as estimated using the AMPLIRUN TOTAL SARS‐CoV‐2 RNA Control (Vircell SA).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

SARS‐CoV‐2 N‐antigenemia in critically ill adult COVID‐19 patients: Frequency and association with inflammatory and tissue‐damage biomarkers

Olea

Albert

Torres

et al. 2021

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

The current study aimed at characterizing the dynamics of SARS-CoV-2 nucleocapsid (N) antigenemia in a cohort of critically ill adult COVID-19 patients and assessing its potential association with plasma levels of biomarkers of clinical severity and mortality. Seventy-three consecutive critically ill COVID-19 patients (median age, 65 years) were recruited. Serial plasma (n = 340) specimens were collected. A lateral flow immunochromatography assay and reverse-transcription polymerase chain reaction (RT-PCR) were used for SARS-CoV-2 N protein detection and RNA quantitation and in plasma, respectively. Serum levels of inflammatory and tissue-damage biomarkers in paired specimens were measured. SARS-CoV-RNA N-antigenemia and viral RNAemia were documented in 40.1% and 35.6% of patients, respectively at a median of 9 days

show abstract

Section: Resultssupporting

confidence: 81%

Section: Resultsmentioning

confidence: 79%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

SARS‐CoV‐2 N‐antigenemia in critically ill adult COVID‐19 patients: Frequency and association with inflammatory and tissue‐damage biomarkers

Olea

Albert

Torres

et al. 2021

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…These findings suggest an underestimated prevalence of conjunctivitis, probably due to false-negative laboratory test results. A study reported the comparison of the viral load found in the plasma and in the tracheal aspirate of COVID-19-positive patients [29]. Eye manifestations can either be due to a direct infection or as a manifestation of systemic inflammatory disease in case COVID-19, as stated by L. Chen et al, in his study [29].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 and the Human Eye: Conjunctivitis, a Lone COVID-19 Finding – A Case-Control Study

et al. 2022

View full text Add to dashboard Cite

Background: The worldwide sudden appearance and drastic increase in the number of infected cases with the severe acute respiratory syndrome-Coronavirus 2 (SARS-CoV-2) determined the World Health Organization to declare it as a pandemic situation. The ‘Corona Virus Disease 2019’ (COVID-19) has varied clinical manifestations, from asymptomatic to severe cases, and conjunctivitis, seems not only to be one of them, but sometimes found to be lone initial symptom present. Aim and method: The aim was to identify the prevalence of conjunctivitis as the first symptom in COVID-19 patients, in a primary healthcare unit. A retrospective study was conducted analyzing the presenting complains/symptoms and results of COVID-19 confirmatory tests. Results: Out of the 672 cases that were sent for RT-PCR testing only 121 (18%) were found to be positive. Among this 2.67% of patients who had both conjunctivitis and COVID-19, 77.77% of patients had unilateral eye affected while 22.22% had bilateral conjunctivitis of varying degrees. 15 patients diagnosed to have both acute conjunctivitis and COVID-19, presented other symptoms associated with COVID-19 infection. While 3 patients had only acute conjunctivitis during their entire course of COVID-19. Conclusions: Conjunctivitis is a symptom of COVID-19 and maybe the first sign of the infection, until the onset of the classical manifestations, the patient serves to be a viral reservoir. The physicians should not miss unilateral conjunctivitis, as it can be the only presenting complain of the COVID-19 disease at the initial phase, which might worsen if underwent undetected and can aid in the spread of the contagion.

show abstract

“…In 1 case, the patient had intermittently detectable RNAaemia for over 200 days from diagnosis and experienced COVID-19 clinical relapses [ 73 ]. Reported serum RNAaemia loads vary between approximately <10–10 6 copies/mL [ 72 , 74 ]. There have been reports of SARS-CoV-2 detection in peripheral blood mononuclear cells [ 75 ] and platelets (PLTs) [ 76 , 77 ].…”

Section: Sars-cov-2: Implications For Blood Safety and Sufficiencymentioning

confidence: 99%

Severe Acute Respiratory Syndrome Coronavirus 2 and Blood Safety: An Updated Review

Kiely

Hoad

Seed

et al. 2022

Transfus Med Hemother

View full text Add to dashboard Cite

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel human coronavirus first identified in late 2019 and subsequently declared a worldwide pandemic in March 2020. In this review, we provide an overview of the implications of SARS-CoV-2 for blood safety and sufficiency. Summary: Approximately one-third of SARS-CoV-2 infections are asymptomatic. The reported mean incubation period typically varies from 2 to 11 days, but longer periods up to 22 days have been reported. The blood phase of SARS-CoV-2 appears to be brief and low level, with RNAaemia detectable in only a small proportion of patients, typically associated with more severe disease and not demonstrated to be infectious virus. A small number of presymptomatic and asymptomatic blood phase cases have been reported. Transfusion-transmission (TT) of SARS-CoV-2 has not been reported. Therefore, the TT risk associated with SARS-CoV-2 is currently theoretical. To mitigate any potential TT risk, but more importantly to prevent respiratory transmission in donor centers, blood services can implement donor deferral policies based on travel, disease status, or potential risk of exposure and encourage staff vaccination. Key Messages: The TT risk of SARS-CoV-2 appears to be low. The biggest risk to blood services in the current COVID-19 pandemic is to maintain the sufficiency of the blood supply while minimizing respiratory transmission of SARS-CoV-2 to donors and staff while donating blood.

show abstract

Lower respiratory tract and plasma SARS-CoV-2 RNA load in critically ill adult COVID-19 patients: Relationship with biomarkers of disease severity

Cited by 13 publications

References 10 publications

SARS‐CoV‐2 N‐antigenemia in critically ill adult COVID‐19 patients: Frequency and association with inflammatory and tissue‐damage biomarkers

SARS‐CoV‐2 N‐antigenemia in critically ill adult COVID‐19 patients: Frequency and association with inflammatory and tissue‐damage biomarkers

COVID-19 and the Human Eye: Conjunctivitis, a Lone COVID-19 Finding – A Case-Control Study

Severe Acute Respiratory Syndrome Coronavirus 2 and Blood Safety: An Updated Review

Contact Info

Product

Resources

About